ERBB2 and breast carcinoma: Introduction: Trastuzumab deruxtecan (T-DXd) is a HER2-directed antibody-drug conjugate indicated for the treatment of unresectable or metastatic HER2-positive breast cancer in patients who have received a prior anti-HER2-based regimen.